Diagnostic imaging and therapeutic agents to help identify and treat disease and improve patient care
Improved diagnostic information for better patient management
Lantheus Expands R&D Leadership Team with Key New Hires
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
Providing you with important information regarding our response to the C0VID-19 pandemic.
(updated 1/8/2021)
View a Lantheus webinar:
COVID-19: Clinical Experiences from the Front Line in NYC
Lantheus Expands R&D Leadership Team with Key New Hires
Lantheus Announces Retirement of Michael P. Duffy, Senior Vice President and General Counsel
Lantheus Acquires Rights to Innovative Imaging Biomarker Targeting Fibroblast Activation Protein (FAP) from Noria
At Lantheus, we develop, manufacture and commercialize essential diagnostic imaging agents and products that help healthcare professionals identify disease and improve patient treatment and care.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.
We are developing next generation imaging agents to enhance the accuracy, reliability and safety of diagnostic imaging.
Setting the standard for diagnostic quality, safety and commitment with the leading echocardiography contrast agent in North America.